FRONT-LINE THERAPIES

STG III, IV
PHASE 3 GOG 3015/Roche
YO39523 (16-2745)
Carbo/Taxol/Bev/Atezolizumab
- ECOG 0-2
- Allows for primary cytoreductive surgery or interval debulking surgery
Current Enrollment = 0/1300
UCH Enrollment =
Local PI: Kian Behbakht

ALL-COMERS

GTFB (07-0935)
TISSUE BANK
ALL GYN TISSUE
Local PI: Kian Behbakht

COMPLETE RESPONSE TO FRONT-LINE – Non Therapeutic

GOG 225 (13-1576)
Diet and Physical Activity
Current Enrollment = 1047/1150
UCH Enrollment = 12
Local PI: Saketh Guntupalli

Gyn tools/ study flow sheet
RECURRENT OVARIAN CANCER CLINICAL TRIALS

Platinum-Sensitive Disease

SOLO 3 (14-2204)
PH 3 Open Label
Olaparib vs physician’s choice single agent chemo for BRCA1/2 mutations
Olaparib vs paclitaxel or topotecan or PLD or gemcitabine
At least 2 prior platinum treatment regimens
More than 4 prior regimens allowed
Current Enrollment =243/250
UCH Enrollment = 4
Local PI: Kian Behbakht

NRG GY004 (16-0707)
PH 3 Single Agent Olaparib or combo Olaparib and Cediranib Compared to Standard Platinum Chemo
Olaparib vs paclitaxel or topotecan or PLD or gemcitabine
Unlimited number of prior platinum based therapies allowed /up to 1 non-platinum therapy for recurrence/Bev allowed for upfront treatment not recurrent
Current Enrollment = 478/561
UCH Enrollment = 7
Local PI: Saketh Guntupalli

ETCTN (17-1240)
LAO-MN026/#8329
PH 1/2 of ABT-888 and Topotecan in patients with Relapsed Ovarian or Primary Peritoneal After Prior Platinum
ABT-888 and Topotecan < than 3 lines prior treatment allowed
Measurable disease required
No Prior use of Parp inhibitor of Topotecan allowed
Current Enrollment =0/102
UCH Enrollment =
Local PI: Brad Corr

Morphotek (15-0343)
PH 2 double blind placebo controlled study of Farletuzumab in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin
Patients must have low CA125 (<3x’s ULN) and measurable disease
Only one prior treatment allowed
Current Enrollment =148/210
UCH Enrollment = 1
Local PI: Kian Behbakht

IIT (17-1333)
PH 1 of SBRT for Patients with Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma
Initial oligorecurrence defined as first recurrence after initial standard of care surgery and chemotherapy with 3 or less sites of disease or Subsequent oligorecurrence limited to 3 or less sites of disease or Oligoproggressive disease defined as 3 or less sites of active disease in the setting of otherwise controlled additional systemic disease.
Systemic Therapy allowed
No limit of on prior lines of systemic therapy
Current Enrollment =0/
UCH Enrollment =
Local PI: Christine Fisher

LOW GRADE
RECURRENT OVARIAN CANCER CLINICAL TRIALS

**NRG GY005 (16-0708)**
PH 2/3 Combo Olaparib/Cediranib compared to Olaparib or Cediranib alone or SOC for recurrent Platinum-Resistant or Refractory Ovarian Phase II - Randomized - Olap. & Cediranib vs Olap. vs Cediranib vs standard non-platinum chemo
Must have received prior bevacizumab and/or >2 prior therapies
No more than 2 prior treatments allowed /Bev allowed for upfront treatment
Current Enrollment = 213/650
UCH Enrollment = 2
Local PI: Saketh Guntupalli
Temp. closed for interim analysis 6/16/17

**NRG GY009 (17-1511)**
Randomized Phase II/III of PLD and Atezolizumab vs plus PLD/Bev/Atezo vs PLD/Bev for Platinum Resistant Ovarian
1-2 prior regimens (including primary tx) allowed
Measureable or evaluable disease allowed
Current Enrollment = 7/488
UCH Enrollment = 0
Local PI: Saketh Guntupalli

**OncoMed (16-1225)**
Phase 1b Study of OMP-305B83 plus Weekly Paclitaxel in Subjects with Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Must have received prior bevacizumab and/or >2 prior therapies
Current Enrollment = 6/30
UCH Enrollment = 2
Local PI: Brad Corr

**ETCTN(17-1240)**
LAO-MN026/#8329
PH 1/2 of ABT-888 and Topotecan in patients with Relapsed Ovarian or Primary Peritoneal After Prior Platinum ABT-888 and Topotecan < than 3 lines prior treatment allowed
Measurable disease required
No Prior use of Parp inhibitor of Topotecan allowed
Current Enrollment =0/102
UCH Enrollment =
Local PI: Brad Corr

**ETCTN(17-1240)**
Ph 1 of SBRT for Patients with Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma
Initial oligorecurrence defined as first recurrence after initial standard of care surgery and chemotherapy with 3 or less sites of disease or Subsequent oligorecurrence limited to 3 or less sites of disease or Oligoprogressive disease defined as 3 or less sites of active disease in the setting of otherwise controlled additional systemic disease. Systemic Therapy allowed No limit of on prior lines of systemic therapy
Current Enrollment =0/
UCH Enrollment =
Local PI: Christine Fisher
NEWLY-DX UTERINE LEIOMYOSARCOMA

ADVANCED, PERSISTENT, OR RECURRENT UTERINE CARCINOSARCOMA

GOG 286B (14-1467)
PH II/III
Paclitaxel/Carboplatin/Metformin
Versus
Paclitaxel/Carboplatin/Placebo as initial therapy
Current enrollment = 385/540
UCH enrollment = 1
Local PI: Saketh Guntupalli

Xenetic (17-0913)
Phase II
Sodium Cridanimod + Progestin therapy for patients who have failed progestin monotherapy or are PrR negative
Current Enrollment = 0/72
UCH Enrollment = 0
Local PI: Brad Corr

T3 Study (15-1003)
Pharmamar
Lurbinectidin
No Known mutation
Patients must have received one prior line of chemo
CERVICAL/VULVAR CANCER CLINICAL TRIALS

ALL-COMERS
- GTFB (07-0935)
- TISSUE BANK
- ALL GYN TISSUE

Primary Treatment Locally Advanced

Recurrent Cervical
- ETCTN (Phase II) (17-0458)
  Phase II Study of Atezolizumab (MPDL3280A) in Combination with Bevacizumab I Patients with Recurrent, Persistent or Metastatic Cervical Cancer
  - 1-2 prior therapies allowed
  - Measurable disease
  - Current Enrollment=2/22
  - UCH Enrollment=0
  - Local PI: Corr

Multi-Specific COMERS
- NRG-GY006 (16-0493)
  Phase II RT and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
  - Current Enrollment=54/188
  - UCH Enrollment=0
  - Local PI: Saketh

Vulvar
- T3 Study (15-2301)
  Merck
  Pembrolizumab
  No known mutation
9/21/2017

PHASE I PROGRAM CLINICAL TRIALS

Cervical

Open/Accruing

PENDING

ON HOLD